Small variations accumulate over time
It is approved for type 2 diabetes and chronic weight management in adults with obesity or overweight with weight-related comorbidities, conditions often associated with insulin resistance
User experimentation suggests that longer initial treatment periods (6+ months continuous) support better benefit retention during subsequent breaks, complete discontinuation breaks of 1-2 months show acceptable benefit maintenance for most users, and very extended breaks (3-6+ months) increase risk of regression toward pre-treatment baseline particularly for short initial treatment courses
What insurance companies look for: Common prior authorization criteria include documented BMI meeting the FDA-approved threshold, documentation of weight-related comorbidities (for patients with BMI 27 to 29.9), evidence of previous weight loss attempts (diet, exercise, behavioral modification), a letter of medical necessity from your provider, and sometimes documentation that you have tried and failed other weight loss medications first (step therapy)
Systemic effects are rare in user reports but are not well characterized in published trials
Bimagrumab is a lab-made antibody that blocks a protein called activin type II